Skip to content
The COVID pandemic underscored the reality of medical inequity worldwide, a longstanding issue reflected in clinical trials, particularly regarding the absence of race and […]
BIO 2024: Can data improve clinical trial diversity? Read More »
About 7% of all U.S. adults have experienced long COVID, according to new studies seeking to identify the scope of the problem and define
7% of U.S. adults had long COVID, find new studies Read More »
In 2024, the BIO International Convention is shining a bright light on patients—in line with one of the Biotechnology Innovation Organization’s strategic priorities to
BIO 2024: What patient advocates said about AFPs, Medicare Part D, and more Read More »
With rapid innovations in agriculture, energy, and environmental biotech, the industry must try to educate regulators and the public about the latest scientific advances
BIO 2024: Education can improve regulation, biotech innovators say Read More »
Investing in women’s health is a gold mine that few healthcare investors have yet to tap, according to a new study that has come
BIO 2024: Investing in women’s health is an untapped gold mine Read More »
In August 2020, the World Health Organization (WHO) adopted a global strategy to eliminate cervical cancer in our lifetime. “To eliminate cervical cancer,” according
We can eliminate cervical cancer in our lifetime – here’s how Read More »
On June 7, the U.S. Food and Drug Administration (FDA) approved an expanded age indication for GSK’s Arexvy, making it the first respiratory syncytial
FDA approves Arexvy for patients 50–59 Read More »
With the passage of the Inflation Reduction Act (IRA) and the growing number of prescription drug affordability boards (PDABs), patients and the biotech industry
BIO 2024: PDABs and IRA pose a murky threat to patient access Read More »
Getting government support for a biotech startup no longer need be a slow and painful process, according to staff and fundees of the Advanced
ARPA-H offers fast, flexible support to biotech startups, panelists tell BIO 2024 Read More »
Biopharma supply chains, streamlining regulation, and other critical issues came up when the leader of the U.S. agency regulating drugs spoke with the leader
FDA’s Dr. Califf talks supply chains, clinical trial diversity, and America’s health Read More »
